- Colgate India’s net income for Q1 is 3.21 billion rupees, which is a 12% decrease compared to the same period last year.
- Analysts estimated the net income to be 3.46 billion rupees, so the actual figures missed expectations.
- Revenue for the quarter is reported at 14.2 billion rupees, marking a 4.7% decline from the previous year.
- The revenue also fell short of the estimated 14.79 billion rupees.
- Total costs for the quarter amount to 10.2 billion rupees, which is a slight decrease of 1% year-over-year.
- Other income has dropped significantly by 23%, standing at 179.4 million rupees for the quarter.
- Market sentiment includes 11 buy recommendations, 12 hold ratings, and 11 sell opinions on Colgate India.
A look at Colgate Palmolive (India) Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Colgate-Palmolive (India) is positioned for steady growth and resilience in the long term, as indicated by its Smartkarma Smart Scores. With a top score in the Dividend category and strong Resilience rating, the company’s consistent payouts and ability to weather market uncertainties make it an attractive investment option. While its Value and Momentum scores are moderate, the solid Dividend and Resilience ratings bode well for the company’s stability and income potential.
Specializing in oral and body care products, Colgate-Palmolive (India) Ltd. offers a diverse range of consumer goods including soaps, cosmetics, toothpaste, and shaving brushes. Its emphasis on quality and hygiene underscores its commitment to meeting consumer needs in the personal care sector. Overall, with favorable Dividend and Resilience scores, Colgate-Palmolive (India) appears well-positioned for sustained growth in its sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
